Status:
ACTIVE_NOT_RECRUITING
Role of Metformin in Posterior Capsule Opacification
Lead Sponsor:
Vienna Institute for Research in Ocular Surgery
Conditions:
Cataract
Diabetes Mellitus Type 2
Eligibility:
All Genders
21-105 years
Phase:
NA
Brief Summary
Determination of concentrations of systemically applied metformin in human lens capsule and its ability to lower the proliferation rate of human lens epithelial cells in vitro.
Detailed Description
Cataract remains a leading cause of visual impairment and blindness worldwide, particularly in aging populations. Although several pharmacological approaches have been explored, removal of the lens wi...
Eligibility Criteria
Inclusion
- Age-related cataract
- Diabetes mellitus type II
- Metformin treatment
- Age 21 or older
- Written informed consent prior to surgery
Exclusion
- Diabetes mellitus type I
- Previous ocular surgery or trauma regarding cataract surgery
- Previous vitrectomy
- Pregnancy (pregnancy test will be taken in women of reproductive age)
Key Trial Info
Start Date :
October 12 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT07176338
Start Date
October 12 2022
End Date
October 1 2025
Last Update
September 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vienna Institute for Research in Ocular Surgery (VIROS)
Vienna, Austria, 1140